alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2  CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002  In connection with the annual report on Form 10-K of Amerityre Corporation (the "Company") for the year ended June 30, 2008 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Anders A. Suarez, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  /s/Anders A. Suarez
Anders A. Suarez
Chief Financial Officer
September 12, 2008
EX-35.6


(logo) Situs

Situs Holdings, LLC
2 Embarcadero Center, Suite 1300
San Francisco, CA 94111
Phone: 415.374.2820
Fax: 415.374.2704

Annual Compliance Statement
For period of January 1 through December 31, 2013

Deutsche Mortgage & Asset Receiving Corporation, COMM 2013-CCRE7
Commercial Mortgage Pass-Through Certificates

Depositor: DEUTSCHE MORTGAGE & ASSET RECEIVING CORPORATION
Trustee:  WELLS FARGO BANK, NATIONAL ASSOCIATION
Certificate Administrator:  WELLS FARGO BANK, NATIONAL ASSOCIATION
Operating Advisor: PARK BRIDGE LENDER SERVICES, LLC
17g-5 Info Provider: WELLS FARGO BANK, NATIONAL ASSOCIATION

Pursuant to Section 10.11 of the Pooling and Servicing Agreement, I attest
that:

(A) A review of the activities of Situs Holdings, LLC, as Special Servicer,
    during the period of January 1 through December 31, 2013(the"Reporting
    Period") and of its performance under the Relevant Servicing Criteria has
    been made under my supervision.

(B) To the best of my knowledge, based on such review, Situs Holdings, LLC,
    as Special Servicer, has fulfilled all of its obligations under the
    Pooling and Servicing Agreement in all material respects throughout such
    Reporting Period.


By: /s/ Stacey Ciarlanti
        Stacey Ciarlanti
        Vice President - Compliance

Date: March 31, 2014
§ 320.29 Analytical methods for an in vivo bioavailability or bioequivalence study. ( a ) The analytical method used in an in vivo bioavailability or bioequivalence study to measure the concentration of the active drug ingredient or therapeutic moiety, or its active metabolite(s), in body fluids or excretory products, or the method used to measure an acute pharmacological effect shall be demonstrated to be accurate and of sufficient sensitivity to measure, with appropriate precision, the actual concentration of the active drug ingredient or therapeutic moiety, or its active metabolite(s), achieved in the body.
( b ) When the analytical method is not sensitive enough to measure accurately the concentration of the active drug ingredient or therapeutic moiety, or its active metabolite(s), in body fluids or excretory products produced by a single dose of the test product, two or more single doses may be given together to produce higher concentration if the requirements of § 320.31 are met.
[42 FR 1648, Jan. 7, 1977, as amended at 67 FR 77674, Dec. 19, 2002]
#### § 511.3 Definitions.

As used in this part:

*Contract research organization* means a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor, e.g., design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to the Food and Drug Administration.

*Investigator* means an individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. “Subinvestigator” includes any other individual member of that team.

*Sponsor* means a person who takes responsibility for and initiates a clinical investigation. The sponsor may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual that uses one or more of its own employees to conduct an investigation that it has initiated is a sponsor, not a sponsor-investigator, and the employees are investigators.

*Sponsor-Investigator* means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. The term does not include any person other than an individual. The requirements applicable to a sponsor-investigator under this part include both those applicable to an investigator and a sponsor.

[77 FR 25359, Apr. 30, 2012]
§ 520.1720d Phenylbutazone gel. ( a ) *Specifications.* Each 30 grams of gel contains 4 grams of phenylbutazone.
( b ) *Sponsor.* See No. 061133 in § 510.600(c) of this chapter. require bioequivalency and safety information.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* 1 to 2 grams of phenylbutazone per 500 pounds of body weight, not to exceed 4 grams daily.
( 2 ) *Indications for use.* For relief of inflammatory conditions associated with the musculoskeletal system of horses.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[50 FR 13561, Apr. 5, 1985, as amended at 50 FR 49372, Dec. 2, 1985; 55 FR 8462, Mar. 8, 1990; 66 FR 14073, Mar. 9, 2001; 68 FR 4915, Jan. 31, 2003; 78 FR 28826, May 20, 2014; 84 FR 8973, Mar. 13, 2019]
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

WILLIE L. WYNN, SR.

, Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 17

- 1724

[November 16, 2017 ]

Appeal from the Circuit Court for the Nineteenth Judicial Circuit,

Indian River County ; Cynthia L. Cox , Judge; L.T. Case No s

. 312016CF000147A and 312016CF000627A

.

Carey Haughwout, Public Defender, and James W. McIntire, Assistant

Public Defender, West Palm Beach, for appellant.

Willie L. Wynn, Sr., Lake City, pro se.

Pamela Jo Bondi, Att orney General, Tallahassee, and Alexandra A. De

La Flor, Assistant Attorney General, West Palm Beach, for appellee.

P ER C URIAM

.

Affirmed.

L EVINE

, C IKLIN and F ORST

, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
§ 520.2220e Sulfadimethoxine extended-release bolus. ( a ) *Specifications.* Each extended-release bolus contains 12.5 grams sulfadimethoxine.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.640 of this chapter.
( d ) *Conditions of use in beef cattle and non-lactating dairy cattle* — ( 1 ) *Amount.* Administer one 12.5-gram-sustained-release bolus for the nearest 200 pounds of body weight, i.e., 62.5 milligrams per pound of body weight. Do not repeat treatment for 7 days.
( 2 ) *Indications for use.* For the treatment of shipping fever complex and bacterial pneumonia associated with *Pasteurella* spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with *Fusobacterium necrophorum* sensitive to sulfadimethoxine.
( 3 ) *Limitations.* Do not use in female dairy cattle 20 months of age or older. Do not administer within 12 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28830, May 20, 2014]
§ 26.49 Regulatory cooperation. ( a ) The parties and authorities shall inform and consult with one another, as permitted by law, of proposals to introduce new controls or to change existing technical regulations or inspection procedures and to provide the opportunity to comment on such proposals.
( b ) The parties shall notify each other in writing of any changes to appendix A of this subpart.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.64 Investigator reports. ( a ) *Progress reports.* The investigator shall furnish all reports to the sponsor of the drug who is responsible for collecting and evaluating the results obtained. The sponsor is required under § 312.33 to submit annual reports to FDA on the progress of the clinical investigations.
( b ) *Safety reports.* An investigator must immediately report to the sponsor any serious adverse event, whether or not considered drug related, including those listed in the protocol or investigator brochure and must include an assessment of whether there is a reasonable possibility that the drug caused the event. Study endpoints that are serious adverse events (e.g., all-cause mortality) must be reported in accordance with the protocol unless there is evidence suggesting a causal relationship between the drug and the event (e.g., death from anaphylaxis). In that case, the investigator must immediately report the event to the sponsor. The investigator must record nonserious adverse events and report them to the sponsor according to the timetable for reporting specified in the protocol.
( c ) *Final report.* An investigator shall provide the sponsor with an adequate report shortly after completion of the investigator's participation in the investigation.
( d ) *Financial disclosure reports.* The clinical investigator shall provide the sponsor with sufficient accurate financial information to allow an applicant to submit complete and accurate certification or disclosure statements as required under part 54 of this chapter. The clinical investigator shall promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 63 FR 5252, Feb. 2, 1998; 67 FR 9586, Mar. 4, 2002; 75 FR 59963, Sept. 29, 2010]
[No. 15912-4-III.

Division Three.

January 13, 1998.]

#### Neil Powell, et al., *Appellants,*v. Whitworth Water District No. 2, et al., *Respondents.*

Appeal from a judgment of the Superior Court for Spokane County, No. 95-2-00739-7, Michael E. Donohue, J., entered June 14, 1996. *Affirmed in part*and *reversed in part*by unpublished opinion per Kato, J., concurred in by Kurtz, A.C.J., and Brown, J.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Balance
Sheet, Statement of operations, Statement of Cash Flows and Notes thereto
incorporated in Part I, Item 7 of this Form 10-QSB and is qualified in its
entirety by reference to such financial statements.
</LEGEND>

<S>                                            <C>
<PERIOD-TYPE>                                        6-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-START>                                 JAN-01-1999
<PERIOD-END>                                   JUN-30-1999
<CASH>                                             844,788
<SECURITIES>                                             0
<RECEIVABLES>                                       55,237
<ALLOWANCES>                                         2,659
<INVENTORY>                                              0
<CURRENT-ASSETS>                                   925,197
<PP&E>                                             689,467
<DEPRECIATION>                                     142,639
<TOTAL-ASSETS>                                   1,620,622
<CURRENT-LIABILITIES>                              954,958
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                        167,004
<COMMON>                                            11,731
<OTHER-SE>                                         486,929
<TOTAL-LIABILITY-AND-EQUITY>                     1,620,622
<SALES>                                            198,783
<TOTAL-REVENUES>                                   198,763
<CGS>                                               94,801
<TOTAL-COSTS>                                       94,801
<OTHER-EXPENSES>                                 1,094,169
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  10,857
<INCOME-PRETAX>                                   (992,701)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                               (992,701)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                      (992,701)
<EPS-BASIC>                                        (0.09)
<EPS-DILUTED>                                        (0.09)


</TABLE>
### Surface water supply of the United States 1961-65: Part 8, western Gulf of Mexico basins: Volume 1, basins from Mermentau River to Colorado River

By: Water Resources Division, U.S. Geological Survey

                            https://doi.org/10.3133/wsp1922

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
###### Editorial Note on Part 25

#### Editorial Note:

Nomenclature changes to part 25 appear at 88 FR 45065, July 14, 2023.

#### § 25.1 Purpose.

The National Environmental Policy Act of 1969 (NEPA), as amended, directs that, to the fullest extent possible, the policies, regulations, and public laws of the United States shall be interpreted and administered in accordance with the policies set forth in NEPA. All agencies of the Federal Government shall comply with the procedures in section 102(2) of NEPA except where compliance would be inconsistent with other statutory requirements. The regulations in this part implement section 102(2) of NEPA in a manner that is consistent with FDA's authority under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. This part also supplements the regulations for implementing the procedural provisions of NEPA that were published by the Council on Environmental Quality (CEQ) in 40 CFR parts 1500 through 1508 and the procedures included in the “HHS General Administration Manual, part 30: Environmental Protection” (45 FR 76519 to 76534, November 19, 1980).
|  | Ground Water & Drinking WaterRecent Additions | Contact Us | Print 										Version 										Search: 										EPA Home >					 Water > 					Ground Water & Drinking Water >					                     National Primary Drinking Water Regulations - Synthetic Organic                     Chemicals |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| NATIONAL PRIMARY        DRINKING WATER REGULATIONS
**Contaminant Specific Fact Sheets****Synthetic Organic Chemicals - Consumer Version**
EPA 811-F-95-003-T            October 1995
To see the most current health effects information for each of these         contaminants, please visit          www.epa.gov/safewater/mcl.html.
AdipateEthylene DibromideAlachlorGlyphosateAldicarb/Aldicarb MetabolitesHeptachlor/Heptachlor EpoxideAtrazineHexachlorobenzeneBenzo(a)pyreneHexachlorocyclopentadieneCarbofuranLindaneChlordaneMethoxychlor2,4 - DOxamyl (Vydate)DalaponPentachlorophenolDibromochloropropanePhthalate, di(2-ethylhexyl)DinosebPicloramDioxin(2,3,7,8-TCDD)Polychlorinated BiphenylsDiquatSimazineEndothallToxapheneEndrin2,4,5 - TP (Silvex) |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                |  | Safewater Home | 	  About Our Office | 	  Publications | 	  Calendar | 	  Links | 	  Office of Water | 	  En Español |
|----------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------------------------|
|                                                           |
|                                                                |
| EPA Home | 			Privacy and Security Notice | Contact Us

  |
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3730 Piperonyl butoxide and pyrethrins as components of bags.

Piperonyl butoxide in combination with pyrethrins may be safely used for insect control on bags that are intended for use in contact with dried feed or dried food in compliance with 40 CFR 180.127 and 40 CFR 180.128.

[85 FR 72907, Nov. 16, 2020]
Skip to main content

An official website of the United States government

Here's how you know

**The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

**The site is secure.** A **lock ()** or **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
-       - Superintendent of Documents
      - 2023-09-02T03:54:00-0400
      - Government Publishing Office, Washington, DC 20401
      - Government Publishing Office
      - Government Publishing Office attests that this document has not been altered since it was disseminated by Government Publishing Office
#### § 3474.10 Clarification regarding 2 CFR 200.207.[2]

The Secretary or a pass-through entity may, in appropriate circumstances, designate the specific conditions established under 2 CFR 200.207 as “high-risk conditions” and designate a non-Federal entity subject to specific conditions established under § 200.207 as “high-risk”.

(Authority: 20 U.S.C. 1221e-3, 3474, and 2 CFR part 200)

###### Footnotes -
  3474.10

[2] C. Ref. 2 CFR 200.205, 200.207.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
FINANCIAL STATEMENTS INCLUDED IN TCI PACIFIC COMMUNICATIONS, INC.'S QUARTERLY
REPORT ON FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                   14,703
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         406,055
<DEPRECIATION>                                  17,808
<TOTAL-ASSETS>                               3,416,094
<CURRENT-LIABILITIES>                                0
<BONDS>                                      1,042,011
<PREFERRED-MANDATORY>                          629,551
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     631,750
<TOTAL-LIABILITY-AND-EQUITY>                 3,416,094
<SALES>                                              0
<TOTAL-REVENUES>                               124,952
<CGS>                                                0
<TOTAL-COSTS>                                   42,520
<OTHER-EXPENSES>                                25,793
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              25,307
<INCOME-PRETAX>                                  4,323
<INCOME-TAX>                                     2,126
<INCOME-CONTINUING>                              2,197
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,197
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.12 Antihistamine active ingredients. The active ingredient of the product consists of any of the following when used within the dosage limits established for each ingredient: ( a ) Brompheniramine maleate.
( b ) Chlorcyclizine hydrochloride.
( c ) Chlorpheniramine maleate.
( d ) Dexbrompheniramine maleate.
( e ) Dexchlorpheniramine maleate.
( f ) Diphenhydramine citrate.
( g ) Diphenhydramine hydrochloride.
( h ) Doxylamine succinate.
( i ) Phenindamine tartrate.
( j ) Pheniramine maleate.
( k ) Pyrilamine maleate.
( l ) Thonzylamine hydrochloride.
( m ) Triprolidine hydrochloride.
[57 FR 58374, Dec. 9, 1992, as amended at 59 FR 4218, Jan. 28, 1994]